Article
Molecular mechanisms of resistance to antifolates, a review.
Acta biochimica Polonica - 1 Jan 1995
Banerjee D, Ercikan-Abali E, Waltham M, Schnieders B, Hochhauser D, Li W W, Fan J, Gorlick R, Goker E, Bertino J R
Abstract excerpt
Methotrexate (MTX) is a clinically important antifolate that has been used in combination with other chemotherapeutic agents in the treatment of malignancies including acute lymphocytic leukemia, osteosarcoma, carcinomas of the breast, head and neck, choriocarcinoma and non-Hodgkin's lymphoma. The primary target of MTX is the enzyme dihydrofolate reductase (DHFR) which catalyzes the reduction of folate and...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.
